Avenzo Therapeutics

Our mission at Avenzo centers around developing next-generation #oncology therapies that make a difference in the lives of people living with cancer. Clinical trials are key to advancing cancer research and on Clinical Trials Day, we are grateful for the patients, families, researchers, and site investigators who make this research possible. #ClinicalTrialsDay #CTD2026

May is National Cancer Research Month – a time to celebrate the incredible advances in oncology research that have transformed the lives of millions of people worldwide. #TeamAvenzo is proud to be part of this effort as we strive to advance new therapies for high unmet needs in oncology and deliver better treatment options to people living with cancer. #NationalCancerResearchMonth #NCRM26

At Avenzo, we’re on a journey to develop next-generation oncology therapies that transform cancer treatment and make a difference in patients’ lives. We’re looking for passionate, collaborative, and determined individuals to join #TeamAvenzo. If you’re exploring your next opportunity, visit our talent community to connect with us and explore our open positions: https://lnkd.in/gjP5hQTi #Hiring #Biotech #Careers

We’re pleased to announce the initiation of the combination cohort evaluating our potential best-in-class CDK4 and CDK2 selective inhibitors in the ongoing Phase 1 portion of our ORION-1 Phase 1/2 study, exploring a dual CDK4 and CDK2 selective inhibition approach in patients with HR+/HER2- metastatic #breastcancer.   This milestone marks another step forward as we continue to advance our pipeline and develop next-generation therapies aimed at improving outcomes for patients. Learn more in our press release: https://bit.ly/4efvMWE

We’re excited to announce the acceptance of an abstract for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.   We look forward to sharing updated safety and efficacy results from the Phase 1 portion of our ongoing Phase 1/2 clinical study of our potential best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor. #breastcancer #solidtumors #ASCO26 https://bit.ly/4sRNa7o

Today we celebrate our #TeamAvenzo colleagues in San Diego and around the country - a passionate group united by our mission to develop the next generation of #oncology therapies for patients in need. Thank you for bringing purpose, expertise, and heart to everything you do! #EmployeeAppreciationDay

This month we welcomed two new members of #TeamAvenzo! Ling He joins as executive director, Bioanalytical, and Jim Xia joins as manager, Statistical Programming. We look forward to the contributions they will make as we continue to advance our pipeline of potential best-in-class #oncology therapies for patients with high unmet medical needs.

Today, at the San Antonio Breast Cancer Symposium (#SABCS25), hosted by UT Health San Antonio and the American Association for Cancer Research (AACR), we’re presenting initial clinical results from the Phase 1 portion of our ongoing Phase 1/2 clinical study of our potential best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor. The data showed preliminary clinical activity, including objective responses in patients with HR+/HER2- breast cancer and cyclin E1 (CCNE1)-amplified ovarian cancer, and that it was generally well tolerated. We look forward to presenting these results and advancing the development of this CDK2 inhibitor for patients with #breastcancer. Learn more: https://bit.ly/4rSr4Ci

We are proud to share that the U.S. Food and Drug Administration granted Fast Track designation to our potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate for the treatment of patients with locally advanced or metastatic #urothelialcancer previously treated with enfortumab vedotin.   This designation represents an important step toward delivering meaningful change for patients by advancing next-generation oncology therapies for individuals with high unmet need. Learn more: https://bit.ly/4p1ZCAu

We are pleased to announce the appointment of Scott Lipman, M.B.A., as our new Chief Financial Officer.   In his expanded role as CFO, Scott will lead our finance & accounting functions while continuing to serve as Chief Business Officer, overseeing our business development efforts, as we advance our clinical-stage #oncology programs and prepare for the company’s next stage of growth.   Read the full press release here: https://bit.ly/3LLt5jo